Sale

Cardiac Biomarkers Market

Global Cardiac Biomarkers Market Analysis, Trends, Growth: By Biomarker Type: Creatine Kinase -MB (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA), Others; By Indication; By End User; By Testing Location; Regional Analysis; Competitive Landscape; 2024-2032

Global Cardiac Biomarkers Market Outlook

The global cardiac biomarkers market reached a value of about USD 11.35 billion in 2023. The market is further estimated to grow at a CAGR of 9.90% in the forecast period of 2024-2032 to reach a value of around USD 26.55 billion by 2032.

 

cardiac biomarkers market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Expanding Point of Care Testing Facility to Propel the Market Growth of Cardiac Biomarkers

Based on testing location, the point of care segment is expected to witness robust growth in the market of cardiac biomarkers over the forecast period. This could be attributed to the rising inclination towards point of care testing due to its potential to offer high sensitivity diagnosis. The improved patient management owing to rapid turnaround of results in a user-friendly manner without wasting time is accelerating the development of the market. The point of care offers high-quality biomarker measurements for diverse clinical settings, including acute care, outpatient clinics, clinical research centres, homes, rural areas, and the developing world. The point of care testing facilitates rapid treatment decisions and reduces the pressure on emergency departments. They enable widespread access to affordable cardiac diagnostics as it leads to reduction in overall hospital and laboratory facility costs.

 

Market Segmentation

 

cardiac biomarkers market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Cardiac biomarkers are used to diagnose critical heart conditions by evaluating the heart functioning of a patient. The biomarkers include enzymes, hormones or proteins that show up in the blood under severe stress or any injury and the test measure these cardiac biomarkers to find the seriousness of heart disease.

The market for cardiac biomarkers, by biomarker type, is divided into:

  • Creatine Kinase -MB (CK-MB)
  • Troponins (T and I)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia Modified Albumin (IMA)
  • Others

Based on indication, the market is segmented into:

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others

On the basis of end-user, the market is bifurcated into:

  • Hospitals
  • Speciality Clinics

Based on testing location, the market is divided into:

  • Point of Care
  • Laboratory Testing

 

cardiac biomarkers market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The regional markets for cardiac biomarkers can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Increasing Prevalence of Critical Heart Conditions to Drive the Market Growth of Cardiac Biomarkers

The pandemic bolstered the market for cardiac biomarkers due to the impact of COVID 19 on cardiovascular systems, which led to the rising application of biomarkers in diagnosis and treatment. The increasing cases of cardiac diseases worldwide due to unhealthy lifestyle changes are providing impetus to the market development of cardiac biomarkers. As per the World Health Organisation estimates, approximately 17.9 million people died from cardiovascular diseases in 2019, representing 32% of overall global deaths. The growing awareness about the reliable diagnosis that cardiac biomarkers offer to prevent heart diseases and the developing healthcare infrastructure play a critical role in expanding the market of cardiac biomarkers. The government initiatives to improve the diagnosis and treatment of cardiovascular diseases and the rising approvals of biomarker tests by organisations like the United States Food and Drug Administration is also invigorating the market of cardiac biomarkers. The increasing diagnostic tests offered by market players and the rapid development of novel biomarker tests to support clinicians in cardiac risk identification are expected to augment the market over the forecast period.

 

Key Players in the Global Cardiac Biomarkers Market

The report gives a detailed analysis of the following key players in the global cardiac biomarkers market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • F. Hoffmann-La Roche Ltd
  • Beckman Coulter, Inc.
  • Creative Diagnostics
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Biomarker Type
  • Indication
  • End User
  • Testing Location
  • Region
Breakup by Biomarker Type
  • Creatine Kinase -MB (CK-MB)
  • Troponins (T and I)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia Modified Albumin (IMA)
  • Others
Breakup by Indication
  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others
Breakup by End User
  • Hospitals
  • Speciality Clinics
Breakup by Testing Location
  • Point of Care
  • Laboratory Testing
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • F. Hoffmann-La Roche Ltd
  • Beckman Coulter, Inc.
  • Creative Diagnostics
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments  
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Region
7    Opportunities and Challenges in the Market  
8    Global Cardiac Biomarkers Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Cardiac Biomarkers Historical Market (2018-2023) 
    8.3    Global Cardiac Biomarkers Market Forecast (2024-2032)
    8.4    Global Cardiac Biomarkers Market by Biomarker Type
        8.4.1    Creatine Kinase -MB (CK-MB)
            8.4.1.1    Historical Trend (2018-2023)
            8.4.1.2    Forecast Trend (2024-2032)
        8.4.2    Troponins (T and I)
            8.4.2.1    Historical Trend (2018-2023)
            8.4.2.2    Forecast Trend (2024-2032)
        8.4.3    Myoglobin
            8.4.3.1    Historical Trend (2018-2023)
            8.4.3.2    Forecast Trend (2024-2032)
        8.4.4    Brain Natriuretic Peptide (BNPs) or NT-proBNP
            8.4.4.1    Historical Trend (2018-2023)
            8.4.4.2    Forecast Trend (2024-2032)
        8.4.5    Ischemia Modified Albumin (IMA)
            8.4.5.1    Historical Trend (2018-2023)
            8.4.5.2    Forecast Trend (2024-2032)
        8.4.6    Others
    8.5    Global Cardiac Biomarkers Market by Indication
        8.5.1    Myocardial Infarction
            8.5.1.1    Historical Trend (2018-2023)
            8.5.1.2    Forecast Trend (2024-2032)
        8.5.2    Congestive Heart Failure
            8.5.2.1    Historical Trend (2018-2023)
            8.5.2.2    Forecast Trend (2024-2032)
        8.5.3    Acute Coronary Syndrome
            8.5.3.1    Historical Trend (2018-2023)
            8.5.3.2    Forecast Trend (2024-2032)
        8.5.4    Atherosclerosis
            8.5.4.1    Historical Trend (2018-2023)
            8.5.4.2    Forecast Trend (2024-2032)
        8.5.5    Others
    8.6    Global Cardiac Biomarkers Market by End User
        8.6.1    Hospitals
            8.6.1.1    Historical Trend (2018-2023)
            8.6.1.2    Forecast Trend (2024-2032)
        8.6.2    Speciality Clinics
            8.6.2.1    Historical Trend (2018-2023)
            8.6.2.2    Forecast Trend (2024-2032)
    8.7    Global Cardiac Biomarkers Market by Testing Location
        8.7.1    Point of Care
            8.7.1.1    Historical Trend (2018-2023)
            8.7.1.2    Forecast Trend (2024-2032)
        8.7.2    Laboratory Testing
            8.7.2.1    Historical Trend (2018-2023)
            8.7.2.2    Forecast Trend (2024-2032)    
    8.8    Global Cardiac Biomarkers Market by Region
        8.8.1    North America
            8.8.1.1    Historical Trend (2018-2023) 
            8.8.1.2    Forecast Trend (2024-2032)
        8.8.2    Europe
            8.8.2.1    Historical Trend (2018-2023) 
            8.8.2.2    Forecast Trend (2024-2032)
        8.8.3    Asia Pacific
            8.8.3.1    Historical Trend (2018-2023) 
            8.8.3.2    Forecast Trend (2024-2032)
        8.8.4    Latin America
            8.8.4.1    Historical Trend (2018-2023) 
            8.8.4.2    Forecast Trend (2024-2032)
        8.8.5    Middle East and Africa
            8.8.5.1    Historical Trend (2018-2023) 
            8.8.5.2    Forecast Trend (2024-2032) 
9    North America Cardiac Biomarkers Market Analysis
    9.1    United States of America 
        9.1.1    Historical Trend (2018-2023) 
        9.1.2    Forecast Trend (2024-2032)
    9.2    Canada
        9.2.1    Historical Trend (2018-2023) 
        9.2.2    Forecast Trend (2024-2032)
10    Europe Cardiac Biomarkers Market Analysis
    10.1    United Kingdom
        10.1.1    Historical Trend (2018-2023) 
        10.1.2    Forecast Trend (2024-2032)
    10.2    Germany
        10.2.1    Historical Trend (2018-2023) 
        10.2.2    Forecast Trend (2024-2032)
    10.3    France
        10.3.1    Historical Trend (2018-2023) 
        10.3.2    Forecast Trend (2024-2032)
    10.4    Italy
        10.4.1    Historical Trend (2018-2023) 
        10.4.2    Forecast Trend (2024-2032)
    10.5    Others
11    Asia Pacific Cardiac Biomarkers Market Analysis
    11.1    China
        11.1.1    Historical Trend (2018-2023) 
        11.1.2    Forecast Trend (2024-2032)
    11.2    Japan
        11.2.1    Historical Trend (2018-2023) 
        11.2.2    Forecast Trend (2024-2032)
    11.3    India
        11.3.1    Historical Trend (2018-2023) 
        11.3.2    Forecast Trend (2024-2032)
    11.4    ASEAN
        11.4.1    Historical Trend (2018-2023) 
        11.4.2    Forecast Trend (2024-2032)
    11.5    Australia
        11.5.2    Historical Trend (2018-2023) 
        11.5.2    Forecast Trend (2024-2032)
    11.6    Others
12    Latin America Cardiac Biomarkers Market Analysis
    12.1    Brazil
        12.1.1    Historical Trend (2018-2023) 
        12.1.2    Forecast Trend (2024-2032)
    12.2    Argentina
        12.2.1    Historical Trend (2018-2023) 
        12.2.2    Forecast Trend (2024-2032)
    12.3    Mexico
        12.3.1    Historical Trend (2018-2023) 
        12.3.2    Forecast Trend (2024-2032)
    12.4    Others
13    Middle East and Africa Cardiac Biomarkers Market Analysis
    13.1    Saudi Arabia
        13.1.1    Historical Trend (2018-2023) 
        13.1.2    Forecast Trend (2024-2032)
    13.2    United Arab Emirates
        13.2.1    Historical Trend (2018-2023) 
        13.2.2    Forecast Trend (2024-2032)
    13.3    Nigeria
        13.3.1    Historical Trend (2018-2023) 
        13.3.2    Forecast Trend (2024-2032)
    13.4    South Africa
        13.4.1    Historical Trend (2018-2023) 
        13.4.2    Forecast Trend (2024-2032)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Value Chain Analysis
16    Competitive Landscape

    16.1    Market Structure
    16.2    Company Profiles
        16.2.1    F. Hoffmann-La Roche Ltd
            16.2.1.1    Company Overview
            16.2.1.2    Product Portfolio
            16.2.1.3    Demographic Reach and Achievements
            16.2.1.4    Certifications
        16.2.2    Beckman Coulter, Inc.
            16.2.2.1    Company Overview
            16.2.2.2    Product Portfolio
            16.2.2.3    Demographic Reach and Achievements
            16.2.2.4    Certifications
        16.2.3    Creative Diagnostics
            16.2.3.1    Company Overview
            16.2.3.2    Product Portfolio
            16.2.3.3    Demographic Reach and Achievements
            16.2.3.4    Certifications
        16.2.4    Bio-Rad Laboratories, Inc.
            16.2.4.1    Company Overview
            16.2.4.2    Product Portfolio
            16.2.4.3    Demographic Reach and Achievements
            16.2.4.4    Certifications
        16.2.5    bioMérieux SA
            16.2.5.1    Company Overview
            16.2.5.2    Product Portfolio
            16.2.5.3    Demographic Reach and Achievements
            16.2.5.4    Certifications
        16.2.6    Others
17    Key Trends and Developments in the Market

 

List of Key Figures and Tables

1.    Global Cardiac Biomarkers Market: Key Industry Highlights, 2018 and 2032
2.    Global Cardiac Biomarkers Historical Market: Breakup by Biomarker Type (USD Billion), 2018-2023
3.    Global Cardiac Biomarkers Market Forecast: Breakup by Biomarker Type (USD Billion), 2024-2032
4.    Global Cardiac Biomarkers Historical Market: Breakup by Indication (USD Billion), 2018-2023
5.    Global Cardiac Biomarkers Market Forecast: Breakup by Indication (USD Billion), 2024-2032
6.    Global Cardiac Biomarkers Historical Market: Breakup by End-User (USD Billion), 2018-2023
7.    Global Cardiac Biomarkers Market Forecast: Breakup by End-User (USD Billion), 2024-2032
8.    Global Cardiac Biomarkers Historical Market: Breakup by Testing Location (USD Billion), 2018-2023
9.    Global Cardiac Biomarkers Market Forecast: Breakup by Testing Location (USD Billion), 2024-2032
10.    Global Cardiac Biomarkers Historical Market: Breakup by Region (USD Billion), 2018-2023
11.    Global Cardiac Biomarkers Market Forecast: Breakup by Region (USD Billion), 2024-2032
12.    North America Cardiac Biomarkers Historical Market: Breakup by Country (USD Billion), 2018-2023
13.    North America Cardiac Biomarkers Market Forecast: Breakup by Country (USD Billion), 2024-2032
14.    Europe Cardiac Biomarkers Historical Market: Breakup by Country (USD Billion), 2018-2023
15.    Europe Cardiac Biomarkers Market Forecast: Breakup by Country (USD Billion), 2024-2032
16.    Asia Pacific Cardiac Biomarkers Historical Market: Breakup by Country (USD Billion), 2018-2023
17.    Asia Pacific Cardiac Biomarkers Market Forecast: Breakup by Country (USD Billion), 2024-2032
18.    Latin America Cardiac Biomarkers Historical Market: Breakup by Country (USD Billion), 2018-2023
19.    Latin America Cardiac Biomarkers Market Forecast: Breakup by Country (USD Billion), 2024-2032
20.    Middle East and Africa Cardiac Biomarkers Historical Market: Breakup by Country (USD Billion), 2018-2023
21.    Middle East and Africa Cardiac Biomarkers Market Forecast: Breakup by Country (USD Billion), 2024-2032
22.    Global Cardiac Biomarkers Market Structure.

Key Questions Answered in the Report

In 2023, the global cardiac biomarkers market attained a value of nearly USD 11.35 billion.

The market is assessed to grow at a CAGR of 9.90% between 2024 and 2032.

The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach almost USD 26.55 billion by 2032.

The major market drivers include the rising importance of cardiac biomarkers in treating heart diseases, developing healthcare infrastructure, and the expansion of point of care facilities.

The key market trends guiding the growth of the market include the increasing cases of heart diseases, government initiatives in approving the biomarker diagnostic tests, and development of novel cardiac biomarker tests by market players.

The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

The significant biomarker types of cardiac biomarkers include Creatine Kinase -MB (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, and Ischemia Modified Albumin (IMA), among others.

The various indications of the market, include myocardial infarction, congestive heart failure, acute coronary syndrome, and atherosclerosis, among others.

The major end users of the market include hospitals and speciality clinics.

The different testing locations of cardiac biomarkers, include point of care and laboratory testing.

The major players in the market are F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Creative Diagnostics, Bio-Rad Laboratories, Inc., and bioMérieux SA, among others.

Analyst Review

The global cardiac biomarkers market attained a value of nearly USD 11.35 billion in 2023, driven by the increasing cases of critical heart conditions. Aided by the development of cardiac biomarker tests by market players, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 9.90%. The market is estimated to reach about USD 26.55 billion by 2032.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The market for cardiac biomarkers, by biomarker type, is divided into Creatine Kinase -MB (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, and Ischemia Modified Albumin (IMA), among others. Based on indication, the market is segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, and atherosclerosis, among others. On the basis of end user, the market is classified into hospitals and speciality clinics. Based on testing location, the market is bifurcated into point of care and laboratory testing. The major regional markets for cardiac biomarkers are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Creative Diagnostics, Bio-Rad Laboratories, Inc., and bioMérieux SA, among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER